Silo Pharma Inc.is a developmental stage biopharmaceutical company dedicated to creating innovative treatments for underserved conditions such as PTSD, stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. By acquiring and licensing technology rights and intellectual property from leading universities and researchers, Silo Pharma integrates traditional therapeutics with psychedelic research to develop novel therapies. Their lead program, SPC-15, is an intranasal formulation targeting PTSD and stress-induced anxiety disorders. Additionally, SP-26 is a time-release ketamine-loaded implant designed for fibromyalgia and chronic pain relief. The company's preclinical programs include SPC-14, an intranasal compound for Alzheimer's disease treatment, and SPU-16, a CNS-homing peptide targeting multiple sclerosis. Silo Pharma's strategic collaborations with institutions like Columbia University and the University of Maryland, Baltimore, enhance their research and development efforts. By pursuing the streamlined 505(b)(2) regulatory pathway, the company aims to reduce costs and expedite the approval process, bringing effective treatments to patients with limited options.